Circulating fibroblast growth factor-21 in coronary artery disease: a systematic review and meta-analysis
Irish Journal of Medical Science (1971 -) · 2026-10 · 195 (5) · 2707-2717
DOI: 10.1007/s11845-026-04472-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Irish Journal of Medical Science (1971 -), online erschienen am 03.06.2026. Verfasst von Feryal Shawa und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Graduate Studies, Molecular Medicine Program, Istanbul Aydin University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Coronary Artery Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul Aydın University.
Abstract (Originalsprache)
Background
Fibroblast growth factor-21 (FGF21) is a metabolic regulator involved in glucose and lipid homeostasis and has emerged as a potential biomarker in cardiometabolic diseases. The relationship between circulating FGF21 levels and coronary artery disease (CAD) remains unclear. We performed a systematic review and meta-analysis to clarify this association and assess its clinical relevance.
Methods
PubMed, Web of Science, and Scopus were searched for observational studies reporting circulating FGF21 levels in adult CAD patients. Standardized mean differences (SMDs) with 95% confidence intervals were calculated using a random-effects model. Subgroup and meta-regression analyses were conducted to explore heterogeneity.
Results
Fourteen studies including 2963 CAD patients were analyzed. Circulating FGF21 levels were significantly higher in CAD patients than in controls (SMD = 0.90; 95% CI: 0.26–1.54; p = 0.0056). In acute CAD, the increase was more pronounced (SMD = 1.70; 95% CI: 0.20–3.21). Elevated FGF21 persisted even when diabetes prevalence was low (SMD = 1.50; 95% CI: 0.15–2.84). Meta-regression identified BMI and HDL as independent contributors to inter-study variability. Sensitivity analyses confirmed robustness, and no strong evidence of publication bias was detected.
Conclusions
Circulating FGF21 is elevated in CAD, primarily reflecting metabolic disturbances—particularly adiposity and dyslipidemia—rather than diabetes or CAD itself. Levels tend to be higher during acute events, suggesting that FGF21 may serve as a marker of metabolic stress and lipid abnormalities rather than a direct diagnostic biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Graduate Studies, Molecular Medicine Program, Istanbul Aydin University, Istanbul, Turkey.
- Department of Medical Biology, Faculty of Medicine, Istanbul Aydin University, Istanbul, Turkey. gulsahkoc@aydin.edu.tr.
Förderung
- Istanbul Aydın University
Zitieren
APA
Shawa, F., Izzeddin, F., & Koc, G. (2026). Circulating fibroblast growth factor-21 in coronary artery disease: a systematic review and meta-analysis. Irish Journal of Medical Science (1971 -), 195(5), 2707-2717. https://doi.org/10.1007/s11845-026-04472-2
Vancouver
Shawa F, Izzeddin F, Koc G. Circulating fibroblast growth factor-21 in coronary artery disease: a systematic review and meta-analysis. Irish Journal of Medical Science (1971 -). 2026;195(5):2707-2717. doi:10.1007/s11845-026-04472-2
BibTeX
@article{Shawa2026,
author = {Shawa, Feryal and Izzeddin, Fatma and Koc, Gulsah},
title = {Circulating fibroblast growth factor-21 in coronary artery disease: a systematic review and meta-analysis},
journal = {Irish Journal of Medical Science (1971 -)},
year = {2026},
volume = {195},
number = {5},
pages = {2707--2717},
doi = {10.1007/s11845-026-04472-2}
}
EUVIMED